icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
TRU-MP2-22 / AMaRC 22-02 - More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures

Treatment of multiple myeloma (MM) is now very complex and costly. However, survival benefits achieved with new therapies in clinical trials are not being seen in clinical practice, in part because many MM patients stop therapy early, often due to side-effects.

The MY-PROMPT-2 trial tests whether real-time symptom feedback using patient-reported outcome measures improves duration on treatment, leading to better patient outcomes and more efficient use of these high-cost medicines.

MY-PROMPT-2 is a collaboration between the Transfusion Research Unit (TRU) at Monash University and AMaRC.

Trial Management Centre: Transfusion Research Unit, Monash University

 

STATUS

Actively recruiting

 

CURRENT ENROLMENT

8 Patients

Recruitment updated as of January 2024

 

STUDY DESIGN

A parallel, non-blinded, multicentre, Bayesian randomised control trial

 

OPTIONAL SUB-STUDIES

Qualitative Interview Sub-Study

This sub-study will explore patient, clinician, and hospital staff's experience of the trial and the intervention.

Economic Evaluation Sub-Study

This sub-study will look to determine the cost-effectiveness of real-time feedback of patient-reported outcome measures.

 

TRIAL PRINCIPAL INVESTIGATORS

Coordinating Principal Investigator: Professor Andrew Spencer, Monash University & AMaRC

Dr Sueh-li Lim, Alfred Health

 

TIME FRAME

2023 – 2027

 

PARTICIPANTS

Patients with relapsed multiple myeloma receiving standard-of-care treatment (daratumumab, lenalidomide, or carfilzomib based therapies) who are registered on the MRDR.

 

SITE LOCATIONS

Alfred Hospital, VIC

Epworth HealthCare, VIC

Princess Alexandra Hospital, QLD

Royal Prince Alfred Hospital, NSW

Austin Health, VIC